Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline.

Lee PS, Lapointe G, Madera AM, Simmons RL, Xu W, Yifru A, Tjandra M, Karur S, Rico A, Thompson K, Bojkovic J, Xie L, Uehara K, Liu A, Shu W, Bellamacina C, McKenney D, Morris L, Tonn GR, Osborne C, Benton BM, McDowell L, Fu J, Sweeney ZK.

J Med Chem. 2018 Oct 25;61(20):9360-9370. doi: 10.1021/acs.jmedchem.8b01287. Epub 2018 Oct 3.

PMID:
30226381
2.

Discovery and Optimization of Phosphopantetheine Adenylyltransferase Inhibitors with Gram-Negative Antibacterial Activity.

Skepper CK, Moreau RJ, Appleton BA, Benton BM, Drumm JE 3rd, Feng BY, Geng M, Hu C, Li C, Lingel A, Lu Y, Mamo M, Mergo W, Mostafavi M, Rath CM, Steffek M, Takeoka KT, Uehara K, Wang L, Wei JR, Xie L, Xu W, Zhang Q, de Vicente J.

J Med Chem. 2018 Apr 26;61(8):3325-3349. doi: 10.1021/acs.jmedchem.7b01861. Epub 2018 Apr 13.

PMID:
29551072
3.

Fragment-Based Drug Discovery of Inhibitors of Phosphopantetheine Adenylyltransferase from Gram-Negative Bacteria.

Moreau RJ, Skepper CK, Appleton BA, Blechschmidt A, Balibar CJ, Benton BM, Drumm JE 3rd, Feng BY, Geng M, Li C, Lindvall MK, Lingel A, Lu Y, Mamo M, Mergo W, Polyakov V, Smith TM, Takeoka K, Uehara K, Wang L, Wei JR, Weiss AH, Xie L, Xu W, Zhang Q, de Vicente J.

J Med Chem. 2018 Apr 26;61(8):3309-3324. doi: 10.1021/acs.jmedchem.7b01691. Epub 2018 Apr 9.

PMID:
29498517
4.

Optimization of CoaD Inhibitors against Gram-Negative Organisms through Targeted Metabolomics.

Rath CM, Benton BM, de Vicente J, Drumm JE, Geng M, Li C, Moreau RJ, Shen X, Skepper CK, Steffek M, Takeoka K, Wang L, Wei JR, Xu W, Zhang Q, Feng BY.

ACS Infect Dis. 2018 Mar 9;4(3):391-402. doi: 10.1021/acsinfecdis.7b00214. Epub 2017 Dec 22.

PMID:
29243909
5.

Synthesis of ciprofloxacin dimers for evaluation of bacterial permeability in atypical chemical space.

Ross AG, Benton BM, Chin D, De Pascale G, Fuller J, Leeds JA, Reck F, Richie DL, Vo J, LaMarche MJ.

Bioorg Med Chem Lett. 2015 Sep 1;25(17):3468-75. doi: 10.1016/j.bmcl.2015.07.010. Epub 2015 Jul 9.

PMID:
26189081
6.

Studies on the mechanism of telavancin decreased susceptibility in a laboratory-derived mutant.

Song Y, Lunde CS, Benton BM, Wilkinson BJ.

Microb Drug Resist. 2013 Aug;19(4):247-55. doi: 10.1089/mdr.2012.0195. Epub 2013 Apr 3.

7.

In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia.

Krause KM, Blais J, Lewis SR, Lunde CS, Barriere SL, Friedland HD, Kitt MM, Benton BM.

Diagn Microbiol Infect Dis. 2012 Dec;74(4):429-31. doi: 10.1016/j.diagmicrobio.2012.08.010. Epub 2012 Oct 16.

PMID:
23083812
8.

Further insights into the mode of action of the lipoglycopeptide telavancin through global gene expression studies.

Song Y, Lunde CS, Benton BM, Wilkinson BJ.

Antimicrob Agents Chemother. 2012 Jun;56(6):3157-64. doi: 10.1128/AAC.05403-11. Epub 2012 Mar 12.

9.

Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic.

Blais J, Lewis SR, Krause KM, Benton BM.

Antimicrob Agents Chemother. 2012 Mar;56(3):1584-7. doi: 10.1128/AAC.05532-11. Epub 2011 Dec 27.

10.

In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci.

Farrell DJ, Krause KM, Benton BM.

Diagn Microbiol Infect Dis. 2011 Mar;69(3):275-9. doi: 10.1016/j.diagmicrobio.2010.09.017.

PMID:
21353951
11.

In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies.

Krause KM, Barriere SL, Kitt MM, Benton BM.

Diagn Microbiol Infect Dis. 2010 Oct;68(2):181-5. doi: 10.1016/j.diagmicrobio.2010.05.008.

PMID:
20846593
12.

Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.

Hill CM, Krause KM, Lewis SR, Blais J, Benton BM, Mammen M, Humphrey PP, Kinana A, Janc JW.

Antimicrob Agents Chemother. 2010 Jul;54(7):2814-8. doi: 10.1128/AAC.01737-09. Epub 2010 Apr 19.

13.

Fluorescence microscopy demonstrates enhanced targeting of telavancin to the division septum of Staphylococcus aureus.

Lunde CS, Rexer CH, Hartouni SR, Axt S, Benton BM.

Antimicrob Agents Chemother. 2010 May;54(5):2198-200. doi: 10.1128/AAC.01609-09. Epub 2010 Feb 22.

14.

Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.

Hegde SS, Skinner R, Lewis SR, Krause KM, Blais J, Benton BM.

J Antimicrob Chemother. 2010 Apr;65(4):725-8. doi: 10.1093/jac/dkq028. Epub 2010 Feb 5.

PMID:
20139142
15.

Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.

Lunde CS, Hartouni SR, Janc JW, Mammen M, Humphrey PP, Benton BM.

Antimicrob Agents Chemother. 2009 Aug;53(8):3375-83. doi: 10.1128/AAC.01710-08. Epub 2009 May 26.

16.

In vitro activity of telavancin against resistant gram-positive bacteria.

Krause KM, Renelli M, Difuntorum S, Wu TX, Debabov DV, Benton BM.

Antimicrob Agents Chemother. 2008 Jul;52(7):2647-52. doi: 10.1128/AAC.01398-07. Epub 2008 Apr 28.

17.

Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.

Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF.

Antimicrob Agents Chemother. 2008 Jul;52(7):2383-8. doi: 10.1128/AAC.01641-07. Epub 2008 Apr 28.

18.

In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.

Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF.

J Antimicrob Chemother. 2008 Jul;62(1):116-21. doi: 10.1093/jac/dkn124. Epub 2008 Apr 19.

PMID:
18424792
19.

Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.

Gotfried MH, Shaw JP, Benton BM, Krause KM, Goldberg MR, Kitt MM, Barriere SL.

Antimicrob Agents Chemother. 2008 Jan;52(1):92-7. Epub 2007 Oct 8.

20.

Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus.

Reyes N, Skinner R, Benton BM, Krause KM, Shelton J, Obedencio GP, Hegde SS.

J Antimicrob Chemother. 2006 Aug;58(2):462-5. Epub 2006 May 30.

PMID:
16735425
21.

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.

Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, Sandvik E, Hubbard JM, Kaniga K, Schmidt DE Jr, Gao Q, Cass RT, Karr DE, Benton BM, Humphrey PP.

Antimicrob Agents Chemother. 2005 Mar;49(3):1127-34.

22.

Large-scale identification of genes required for full virulence of Staphylococcus aureus.

Benton BM, Zhang JP, Bond S, Pope C, Christian T, Lee L, Winterberg KM, Schmid MB, Buysse JM.

J Bacteriol. 2004 Dec;186(24):8478-89.

23.

The yeast immunophilin Fpr3 is a physiological substrate of the tyrosine-specific phosphoprotein phosphatase Ptp1.

Wilson LK, Benton BM, Zhou S, Thorner J, Martin GS.

J Biol Chem. 1995 Oct 20;270(42):25185-93.

25.
27.

Drosophila nuclear lamin precursor Dm0 is translated from either of two developmentally regulated mRNA species apparently encoded by a single gene.

Gruenbaum Y, Landesman Y, Drees B, Bare JW, Saumweber H, Paddy MR, Sedat JW, Smith DE, Benton BM, Fisher PA.

J Cell Biol. 1988 Mar;106(3):585-96. Erratum in: J Cell Biol 1988 Jun;106(6):2225.

Supplemental Content

Loading ...
Support Center